These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 25402221

  • 21. Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy.
    Porter JB, Elalfy MS, Taher AT, Aydinok Y, Chan LL, Lee SH, Sutcharitchan P, Habr D, Martin N, El-Beshlawy A.
    Ann Hematol; 2013 Jan; 92(2):211-9. PubMed ID: 23086508
    [Abstract] [Full Text] [Related]

  • 22. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.
    Vichinsky E, Torres M, Minniti CP, Barrette S, Habr D, Zhang Y, Files B, study CICL670A2201 investigators.
    Am J Hematol; 2013 Dec; 88(12):1068-73. PubMed ID: 23946212
    [Abstract] [Full Text] [Related]

  • 23. [Curative effects and safety of deferasirox in treatment of iron overload in children with β-thalassemia major].
    Gao HY, Li Q, Chen JJ, Chen GF, Li CG.
    Zhongguo Dang Dai Er Ke Za Zhi; 2011 Jul; 13(7):531-4. PubMed ID: 21752315
    [Abstract] [Full Text] [Related]

  • 24. Reversible Fanconi syndrome in a pediatric patient on deferasirox.
    Rheault MN, Bechtel H, Neglia JP, Kashtan CE.
    Pediatr Blood Cancer; 2011 Apr; 56(4):674-6. PubMed ID: 21298760
    [Abstract] [Full Text] [Related]

  • 25. Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study.
    Taher AT, Cappellini MD, Aydinok Y, Porter JB, Karakas Z, Viprakasit V, Siritanaratkul N, Kattamis A, Wang C, Zhu Z, Joaquin V, Uwamahoro MJ, Lai YR.
    Blood Cells Mol Dis; 2016 Mar; 57():23-9. PubMed ID: 26852651
    [Abstract] [Full Text] [Related]

  • 26. Deferasirox for cardiac siderosis in β-thalassaemia major: a multicentre, open label, prospective study.
    Piga A, Longo F, Origa R, Roggero S, Pinna F, Zappu A, Castiglioni C, Cappellini MD.
    Br J Haematol; 2014 Nov; 167(3):423-6. PubMed ID: 24976388
    [No Abstract] [Full Text] [Related]

  • 27. Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state.
    Waldmeier F, Bruin GJ, Glaenzel U, Hazell K, Sechaud R, Warrington S, Porter JB.
    Drug Metab Dispos; 2010 May; 38(5):808-16. PubMed ID: 20097723
    [Abstract] [Full Text] [Related]

  • 28. Long-term chelation therapy with deferasirox: effects on cardiac iron overload measured by T2* MRI.
    Ruffo GB, Borsellino Z, Cuccia L, Marocco MR, Gagliardotto F, Tarantino R.
    Clin Drug Investig; 2010 May; 30(4):267-73. PubMed ID: 20225910
    [Abstract] [Full Text] [Related]

  • 29. Nephrolithiasis in patients exposed to deferasirox and desferioxamine: probably an age-linked event with different effects on some renal parameters.
    Ricchi P, Ammirabile M, Costantini S, Spasiano A, Di Matola T, Cinque P, Casale M, Filosa A, Prossomariti L.
    Ann Hematol; 2014 Mar; 93(3):525-7. PubMed ID: 23807253
    [No Abstract] [Full Text] [Related]

  • 30. Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia.
    Taher AT, Temraz S, Cappellini MD.
    Expert Rev Hematol; 2013 Oct; 6(5):495-509. PubMed ID: 24083402
    [Abstract] [Full Text] [Related]

  • 31. Iranian experience of deferasirox (Exjade(®)) in transfusion-dependent patients with iron overload: what is the most effective dose based on serum ferritin levels?
    Karimi M, Azarkeivan A, Zareifar S, Cohan N, Bordbar MR, Haghpanah S.
    Hematology; 2012 Nov; 17(6):367-71. PubMed ID: 23168076
    [Abstract] [Full Text] [Related]

  • 32. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up.
    Cappellini MD, Bejaoui M, Agaoglu L, Canatan D, Capra M, Cohen A, Drelichman G, Economou M, Fattoum S, Kattamis A, Kilinc Y, Perrotta S, Piga A, Porter JB, Griffel L, Dong V, Clark J, Aydinok Y.
    Blood; 2011 Jul 28; 118(4):884-93. PubMed ID: 21628399
    [Abstract] [Full Text] [Related]

  • 33. A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes.
    Cermak J, Jonasova A, Vondrakova J, Cervinek L, Belohlavkova P, Neuwirtova R.
    Leuk Res; 2013 Dec 28; 37(12):1612-5. PubMed ID: 23937987
    [Abstract] [Full Text] [Related]

  • 34. Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload.
    Taher A, Cappellini MD, Vichinsky E, Galanello R, Piga A, Lawniczek T, Clark J, Habr D, Porter JB.
    Br J Haematol; 2009 Dec 28; 147(5):752-9. PubMed ID: 19764988
    [Abstract] [Full Text] [Related]

  • 35. Deferasirox for transfusion-related iron overload: a clinical review.
    Lindsey WT, Olin BR.
    Clin Ther; 2007 Oct 28; 29(10):2154-66. PubMed ID: 18042472
    [Abstract] [Full Text] [Related]

  • 36. Long-term effects of an oral iron chelator, deferasirox, in hemodialysis patients with iron overload.
    Chen CH, Shu KH, Yang Y.
    Hematology; 2015 Jun 28; 20(5):304-10. PubMed ID: 25200910
    [Abstract] [Full Text] [Related]

  • 37. Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent β-thalassemia.
    Chang HH, Lu MY, Liao YM, Lin PC, Yang YL, Lin DT, Chiou SS, Jou ST, Lin KH, Chang TT.
    Pediatr Blood Cancer; 2011 Mar 28; 56(3):420-4. PubMed ID: 21072825
    [Abstract] [Full Text] [Related]

  • 38. Deferasirox--an oral agent for chronic iron overload.
    Vanorden HE, Hagemann TM.
    Ann Pharmacother; 2006 Jun 28; 40(6):1110-7. PubMed ID: 16735647
    [Abstract] [Full Text] [Related]

  • 39. Improvement in hematopoiesis after iron chelation therapy with deferasirox in patients with aplastic anemia.
    Lee SE, Yahng SA, Cho BS, Eom KS, Kim YJ, Lee S, Min CK, Kim HJ, Cho SG, Kim DW, Min WS, Park CW, Lee JW.
    Acta Haematol; 2013 Jun 28; 129(2):72-7. PubMed ID: 23154600
    [Abstract] [Full Text] [Related]

  • 40. The long-term efficacy and tolerability of oral deferasirox for patients with transfusion-dependent β-thalassemia in Taiwan.
    Chang HH, Lu MY, Peng SS, Yang YL, Lin DT, Jou ST, Lin KH.
    Ann Hematol; 2015 Dec 28; 94(12):1945-52. PubMed ID: 26404899
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.